Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiac Cycle01:29

Cardiac Cycle

The cardiac cycle refers to the sequence of events that occur in the heart from the beginning of one heartbeat to the next. It's characterized by alternating periods of contraction (systole) and relaxation (diastole) of the heart muscles.
During the cardiac cycle, blood flow through the heart is regulated entirely by changing pressure gradients. This sequence of events begins with the heart in a state of total relaxation, known as mid-to-late diastole, during which blood passively flows from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intracardiac Electrograms During Left Bundle Branch Area Pacing Implantation.

JACC. Clinical electrophysiology·2026
Same author

Predictors of pacing-induced cardiomyopathy in patients undergoing AV nodal ablation: insights from a Delphi process and retrospective cohort study.

European heart journal open·2026
Same author

Bridging the gap: adapting heart failure guidelines for resource-limited settings: A European Journal of Heart Failure expert consensus document.

European journal of heart failure·2026
Same author

[Pacemakers and cardiac resynchronization therapy : recent advances].

Revue medicale suisse·2026
Same author

[Cardiac sarcoidosis in 2026 : current perspectives].

Revue medicale suisse·2026
Same author

Conduction System Pacing With AV Node Ablation Versus Pulmonary Vein Isolation: Emerging Evidence.

JACC. Asia·2026
Same journal

Incidence and Clinical Predictors of Cognitive Decline in Anticoagulated Patients with Atrial Fibrillation. The Strat-AF Study.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same journal

Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation - insights from acute and chronic electroanatomic remapping in the randomized SINGLE-SHOT CHAMPION trial.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same journal

Pulmonary vein reconnection patterns after pentaspline pulsed field ablation for atrial fibrillation.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same journal

Angioplasty for Pulmonary Vein Stenosis after Atrial Fibrillation Ablation.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same journal

Compliance to direct oral anticoagulation therapy and clinical outcomes after catheter ablation for atrial fibrillation: a nationwide cohort study.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same journal

Atrial cardiomyopathy as a multidomain disease: longitudinal evidence for autonomic remodelling.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
See all related articles

Related Experiment Video

Updated: Jun 18, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Right ventricular systolic function and cardiac resynchronization therapy.

Haran Burri1, Giulia Domenichini, Henri Sunthorn

  • 1Cardiology Service, University Hospital of Geneva, 23, Micheli-du-Crest, Geneva 1211, Switzerland. haran.burri@hcuge.ch

Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology
|December 8, 2009
PubMed
Summary
This summary is machine-generated.

Cardiac resynchronization therapy (CRT) offers minimal acute benefit to right ventricular ejection fraction (RVEF). Patients with lower baseline RVEF show reduced response to CRT, suggesting RVEF is crucial for patient selection.

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice
08:21

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice

Published on: June 15, 2020

Related Experiment Videos

Last Updated: Jun 18, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice
08:21

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice

Published on: June 15, 2020

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Management

Background:

  • Right ventricular ejection fraction (RVEF) response to cardiac resynchronization therapy (CRT) is understudied.
  • The influence of baseline RVEF on CRT outcomes remains unclear.

Purpose of the Study:

  • To assess acute and chronic effects of CRT on right ventricular systolic function.
  • To determine if baseline RVEF predicts response to CRT.

Main Methods:

  • Radionuclide angiography used to measure RVEF, LVEF, and right ventricular synchrony.
  • NYHA functional class and 6-minute walking distance (6MWD) assessed at baseline and follow-up.
  • Analysis of 44 patients undergoing CRT implantation.

Main Results:

  • No significant acute changes in RVEF observed post-CRT.
  • RVEF showed slight improvement at follow-up (1.9%), less than LVEF (5.1%).
  • Patients with baseline RVEF ≤ 0.35 had diminished improvement in NYHA class, 6MWD, and LVEF.

Conclusions:

  • CRT has minimal acute impact on RVEF and only modest chronic improvement.
  • Reduced baseline RVEF is associated with poorer response to CRT.
  • Baseline RVEF may be a critical factor in selecting patients for CRT.